Ocular Sarcoidosis

ABSTRACT

Ocular disease occurs in approximately a third of sarcoidosis patients. The rate of disease varies around the world, with Japanese sarcoidosis patients having ocular disease in more than 70% of cases. If untreated, ocular disease can lead to permanent visual impairment, including blindness. The most common manifestation is uveitis, with anterior involvement often being self-limiting, whereas posterior involvement can be chronic. The diagnosis of ocular sarcoidosis in patients with known sarcoidosis usually requires a specific examination by an ophthalmologist. For patients presenting with uveitis of unknown etiology, criteria have been proposed for diagnosing ocular sarcoidosis. The treatment of ocular disease ranges from topical therapy to systemic treatments such as methotrexate. Recent reports have demonstrated that monoclonal antibodies blocking tumor necrosis factor can be quite effective for chronic refractory ocular sarcoidosis.

KEYWORDS

Sarcoidosis - ocular - eye

REFERENCES

• 1 Ohara K, Judson M A, Baughman R P. Clinical Aspects of Ocular Sarcoidosis. In: Drent M, Costabel U Sarcoidosis. Wakefield, UK; Charlesworth Group 2005: 188-209
• 2 Ohara K, Okubo A, Sasaki H, Kamata K. Intraocular manifestations of systemic sarcoidosis.  Jpn J Ophthalmol. 1992;  36 452-457
• 3 Dana M R, Merayo-Lloves J, Schaumberg D A et al.. Prognosticators for visual outcome in sarcoid uveitis.  Ophthalmology. 1996;  103 1846-1853
• 4 Jakob E, Reuland M S, Mackensen F et al.. Uveitis subtypes in a German interdisciplinary uveitis center—analysis of 1916 patients.  J Rheumatol. 2009;  36 127-136
• 5 Judson M A, Baughman R P, Teirstein A S, Terrin M L, Yeager Jr H. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument.  Sarcoidosis Vasc Diffuse Lung Dis. 1999;  16 75-86
• 6 Takahashi T, Azuma A, Abe S, Kawanami O, Ohara K, Kudoh S. Significance of lymphocytosis in bronchoalveolar lavage in suspected ocular sarcoidosis.  Eur Respir J. 2001;  18 515-521
• 7 Hunninghake G W, Costabel U, Ando M et al.. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders.  Sarcoidosis Vasc Diffuse Lung Dis. 1999;  16 149-173
• 8 Herbort C P, Rao N A, Mochizuki M. members of Scientific Committee of First International Workshop on Ocular Sarcoidosis . International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS).  Ocul Immunol Inflamm. 2009;  17 160-169
• 9 Kawaguchi T, Hanada A, Horie S, Sugamoto Y, Sugita S, Mochizuki M. Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis patients.  Jpn J Ophthalmol. 2007;  51 121-126
• 10 Evans M, Sharma O, LaBree L, Smith R E, Rao N A. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis.  Ophthalmology. 2007;  114 325-333
• 11 Pietinalho A, Ohmichi M, Löfroos A B, Hiraga Y, Selroos O. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan: a comparative five-year study of biopsy-proven cases.  Sarcoidosis Vasc Diffuse Lung Dis. 2000;  17 158-166
• 12 Pietinalho A, Ohmichi M, Hiraga Y et al.. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan: a comparative analysis of 571 Finnish and 686 Japanese patients.  Sarcoidosis. 1996;  13 159-166
• 13 Baughman R P, Teirstein A S, Judson M A Case Control Etiologic Study of Sarcoidosis (ACCESS) research group et al. Clinical characteristics of patients in a case control study of sarcoidosis.  Am J Respir Crit Care Med. 2001;  164(10 Pt 1) 1885-1889
• 14 Rothova A, Alberts C, Glasius E, Kijlstra A, Buitenhuis H J, Breebaart A C. Risk factors for ocular sarcoidosis.  Doc Ophthalmol. 1989;  72 287-296
• 15 Prabhakaran V C, Saeed P, Esmaeli B et al.. Orbital and adnexal sarcoidosis.  Arch Ophthalmol. 2007;  125 1657-1662
• 16 Pattishall E N, Strope G L, Spinola S M, Denny F W. Childhood sarcoidosis.  J Pediatr. 1986;  108 169-177
• 17 Shetty A K, Gedalia A. Childhood sarcoidosis: a rare but fascinating disorder.  Pediatr Rheumatol Online J. 2008;  6 16
• 18 Rybicki B A, Maliarik M J, Bock C H et al.. The Blau syndrome gene is not a major risk factor for sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1999;  16 203-208
• 19 Rossman M D, Thompson B, Frederick M ACCESS Group et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites.  Am J Hum Genet. 2003;  73 720-735
• 20 Rybicki B A, Sinha R, Iyengar S, Gray-McGuire C, Elston R C, Iannuzzi M C. SAGA Study Consortium . Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study.  Genes Immun. 2007;  8 379-386
• 21 Spagnolo P, Sato H, Marshall S E et al.. Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis.  Invest Ophthalmol Vis Sci. 2007;  48 3019-3025
• 22 Bradley D A, Baughman R P, Raymond L, Kaufman A H. Ocular manifestations of sarcoidosis.  Semin Respir Crit Care Med. 2002;  23 543-548
• 23 Jabs D A, Johns C J. Ocular involvement in chronic sarcoidosis.  Am J Ophthalmol. 1986;  102 297-301
• 24 Silver M R, Messner L V. Sarcoidosis and its ocular manifestations.  J Am Optom Assoc. 1994;  65 321-327
• 25 Boyd S R, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides.  Surv Ophthalmol. 2001;  46 209-233
• 26 Obenauf C D, Shaw H E, Sydnor C F, Klintworth G K. Sarcoidosis and its ophthalmic manifestations.  Am J Ophthalmol. 1978;  86 648-655
• 27 Rothova A. Ocular involvement in sarcoidosis.  Br J Ophthalmol. 2000;  84 110-116
• 28 Raymond L A, Spaulding A G, Vilter R W. Peripheral retinal neovascularization in sarcoidosis with thalassemia.  Ann Ophthalmol. 1978;  10 745-748
• 29 Steahly L P. Sarcoidosis and peripheral neovascularization.  Ann Ophthalmol. 1988;  20 426-427 430
• 30 Baughman R P, Lower E E, Bradley D A, Raymond L A, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.  Chest. 2005;  128 1062-47
• 31 Rothova A, Suttorp-van Schulten M S, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease.  Br J Ophthalmol. 1996;  80 332-336
• 32 Mayers M. Ocular sarcoidosis.  Int Ophthalmol Clin. 1990;  30 257-263
• 33 Zajicek J P, Scolding N J, Foster O et al.. Central nervous system sarcoidosis—diagnosis and management.  QJM. 1999;  92 103-117
• 34 Lower E E, Broderick J P, Brott T G, Baughman R P. Diagnosis and management of neurological sarcoidosis.  Arch Intern Med. 1997;  157 1864-1868
• 35 Baughman R P, Bradley D A, Lower E E. Infliximab in chronic ocular inflammation.  Int J Clin Pharmacol Ther. 2005;  43 7-11
• 36 Salama B, Gicquel J J, Lenoble P, Dighiero P L. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist.  Can J Ophthalmol. 2006;  41 766-768
• 37 Mumoli N, Niccoli G, Scazzeri F, Picchietti S, Greco A, Cei M. Infliximab-induced retrobulbar optic neuritis.  QJM. 2007;  100 531
• 38 Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.  Ann Rheum Dis. 2007;  66 1255-1258
• 39 Peterson E A, Hymas D C, Pratt D V, Mortenson S W, Anderson R L, Mamalis N. Sarcoidosis with orbital tumor outside the lacrimal gland: initial manifestation in 2 elderly white women.  Arch Ophthalmol. 1998;  116 804-806
• 40 Linberg J V, McCormick S A. Primary acquired nasolacrimal duct obstruction: a clinicopathologic report and biopsy technique.  Ophthalmology. 1986;  93 1055-1063
• 41 Anderson N G, Wojno T H, Grossniklaus H E. Clinicopathologic findings from lacrimal sac biopsy specimens obtained during dacryocystorhinostomy.  Ophthal Plast Reconstr Surg. 2003;  19 173-176
• 42 Merkonidis C, Brewis C, Yung M, Nussbaumer M. Is routine biopsy of the lacrimal sac wall indicated at dacryocystorhinostomy? A prospective study and literature review.  Br J Ophthalmol. 2005;  89 1589-1591
• 43 Baughman R P, Lower E E, Tami T. Upper airway, IV: Sarcoidosis of the upper respiratory tract (SURT).  Thorax. 2010;  65 181-186
• 44 Yanardag H, Pamuk O N. Lacrimal gland involvement in sarcoidosis. The clinical features of 9 patients.  Swiss Med Wkly. 2003;  133 388-391
• 45 DeRemee R A. Sarcoidosis and Wegener’s granulomatosis: a comparative analysis.  Sarcoidosis. 1994;  11 7-18
• 46 Wertheim M S, Mathers W D, Suhler E B, Wilson D J, Rosenbaum J T. Histopathological features of conjunctival sarcoid nodules using noninvasive in vivo confocal microscopy.  Arch Ophthalmol. 2005;  123 274-276
• 47 Samson C M, Waheed N, Baltatzis S, Foster C S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients.  Ophthalmology. 2001;  108 1134-1139
• 48 Baughman R P, Lower E E. Sarcoidosis. In: Fauci AS, Braunwald E, Kasper DL, et al Harrison's Principles of Internal Medicine. New York; McGraw-Hill 2008: 2135-2142
• 49 Ohara K, Okubo A, Kamata K, Sasaki H, Kobayashi J, Kitamura S. Transbronchial lung biopsy in the diagnosis of suspected ocular sarcoidosis.  Arch Ophthalmol. 1993;  111 642-644
• 50 Clement D S, Postma G, Rothova A, Grutters J C, Prokop M, de Jong P A. Intraocular sarcoidosis: association of clinical characteristics of uveitis with positive chest high-resolution computed tomography findings.  Br J Ophthalmol. 2010;  94 219-222
• 51 Baughman R P, Drent M. Role of bronchoalveolar lavage in interstitial lung disease.  Clin Chest Med. 2001;  22 331-341
• 52 Bienfait M F, Hoogsteden H C, Baarsma G S, Adriaansen H J, Verheijen-Breemhaar L. Diagnostic value of bronchoalveolar lavage in ocular sarcoidosis.  Acta Ophthalmol (Copenh). 1987;  65 745-748
• 53 Jouveshomme S, Fardeau C, Finet J F et al.. Alveolar lymphocytosis in patients with chronic uveitis: relationship to sarcoidosis.  Lung. 2001;  179 305-317
• 54 Controlled evaluation of loteprendnol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol etabonate US uveitis study.  Am J Ophthalmol. 1999;  127 537-544
• 55 Hirano Y, Ito T, Nozaki M et al.. Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes.  Jpn J Ophthalmol. 2009;  53 519-522
• 56 Eljarrat-Binstock E, Pe’er J, Domb A J. New techniques for drug delivery to the posterior eye segment.  Pharm Res. 2010;  27 530-543
• 57 Pavesio C, Zierhut M, Bairi K, Comstock T L, Usner D W. Fluocinolone Acetonide Study Group . Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.  Ophthalmology. 2010;  117 567-575 e1
• 58 Kempen J H, Altaweel M M, Holbrook J T, Jabs D A, Sugar E A. Multicenter Uveitis Steroid Treatment Trial Research Group . The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.  Am J Ophthalmol. 2010;  149 550-561 e10
• 59 Galor A, Jabs D A, Leder H A et al.. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.  Ophthalmology. 2008;  115 1826-1832
• 60 Baughman R P, Costabel U, du Bois R M. Treatment of sarcoidosis.  Clin Chest Med. 2008;  29 533-548 ix-x
• 61 Dev S, McCallum R M, Jaffe G J. Methotrexate treatment for sarcoid-associated panuveitis.  Ophthalmology. 1999;  106 111-118
• 62 Veien N K. Cutaneous sarcoidosis: prognosis and treatment.  Clin Dermatol. 1986;  4 75-87
• 63 Baughman R P, Lower E E, Bradley D A et al.. Use of cytotoxic therapy for chronic ophthalmic sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1999;  16 S17
• 64 Shetty A K, Zganjar B E, Ellis Jr G S, Ludwig I H, Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis.  J Pediatr Ophthalmol Strabismus. 1999;  36 125-128
• 65 Maust H A, Foroozan R, Sergott R C, Niazi S, Weibel S, Savino P J. Use of methotrexate in sarcoid-associated optic neuropathy.  Ophthalmology. 2003;  110 559-563
• 66 Lower E E, Baughman R P. The use of low dose methotrexate in refractory sarcoidosis.  Am J Med Sci. 1990;  299 153-157
• 67 Taylor S R, Habot-Wilner Z, Pacheco P, Lightman S L. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema.  Ophthalmology. 2009;  116 797-801
• 68 Baughman R P, Lower E E. Alternatives to corticosteroids in the treatment of sarcoidosis.  Sarcoidosis. 1997;  14 121-130
• 69 Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen.  Eur Respir J. 1999;  14 1117-1122
• 70 Pasadhika S, Kempen J H, Newcomb C W et al.. Azathioprine for ocular inflammatory diseases.  Am J Ophthalmol. 2009;  148 500-509 e2
• 71 Deuter C M, Doycheva D, Stuebiger N, Zierhut M. Mycophenolate sodium for immunosuppressive treatment in uveitis.  Ocul Immunol Inflamm. 2009;  17 415-419
• 72 Bhat P, Cervantes-Castañeda R A, Doctor P P, Anzaar F, Foster C S. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis.  Ocul Immunol Inflamm. 2009;  17 185-190
• 73 Baughman R P, Lower E E. Leflunomide for chronic sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2004;  21 43-48
• 74 Reiff A, Takei S, Sadeghi S et al.. Etanercept therapy in children with treatment-resistant uveitis.  Arthritis Rheum. 2001;  44 1411-1415
• 75 Foster C S, Tufail F, Waheed N K et al.. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate.  Arch Ophthalmol. 2003;  121 437-440
• 76 Smith J A, Thompson D J, Whitcup S M et al.. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.  Arthritis Rheum. 2005;  53 18-23
• 77 Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis.  Rheumatology (Oxford). 2005;  44 1008-1011
• 78 Hashkes P J, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy.  Clin Exp Rheumatol. 2003;  21 645-646
• 79 Galor A, Perez V L, Hammel J P, Lowder C Y. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.  Ophthalmology. 2006;  113 2317-2323
• 80 Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.  Ann Rheum Dis. 2007;  66 548-550
• 81 Diaz-Llopis M, García-Delpech S, Salom D et al.. Adalimumab therapy for refractory uveitis: a pilot study.  J Ocul Pharmacol Ther. 2008;  24 351-361
• 82 Tynjälä P, Kotaniemi K, Lindahl P et al.. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.  Rheumatology (Oxford). 2008;  47 339-344
• 83 Sandborn W J, Hanauer S, Loftus Jr E V et al.. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease.  Am J Gastroenterol. 2004;  99 1984-1989
• 84 Lim L L, Fraunfelder F W, Rosenbaum J T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.  Arthritis Rheum. 2007;  56 3248-3252
• 85 Daïen C I, Monnier A, Claudepierre P Club Rhumatismes et Inflammation (CRI) et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.  Rheumatology (Oxford). 2009;  48 883-886
• 86 Ramos-Casals M, Brito-Zerón P, Soto M J, Cuadrado M J, Khamashta M A. Autoimmune diseases induced by TNF-targeted therapies.  Best Pract Res Clin Rheumatol. 2008;  22 847-861
• 87 Sweiss N J, Baughman R P. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?.  J Rheumatol. 2007;  34 2129-2131
• 88 Crick P P, Hoyle C, Smellie H. The eye in sarcoidosis.  Br J Dis Chest. 1961;  45 461-481
• 89 James D G, Anderson R, Langley D, Ainslie D. Ocular sarcoidosis.  Br J Ophthalmol. 1964;  48 461-470
• 90 Karma A, Huhti E, Poukkula A. Course and outcome of ocular sarcoidosis.  Am J Ophthalmol. 1988;  106 467-472